Please note: The information displayed on this page might be outdated.
Intensity Therapeutics: Subsidiary of Portage Biotech (seed investor in Biohaven). Raised $10m Series A in June 2016 (Investors: FastForward Innovations, Batterson VC, VCapital, Declan Doogan, Jim Mellon). DfuseRx℠ platform technology can rapidly ID tissue dispersion and cell penetrating anti-cancer formulation for a given tumor type. Initiated FIH trial to study effects in solid tumors; trial aims to enroll 60 patients w different types of advanced solid tumor malignancies in a multicycle dosing regimen
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - New England
Clinical Stage
Phase l or ll
Disease Space
Oncology
Industry
Biotechnology
Listing
Private
Website:
Address:
8 Wright Street
Suite 107
Westport, CT 06880
United States

Company Participants at Boston Private Company Showcase

  • Ian B Walters